A Randomized, Single-center, Open-label, One-sequence, Two-period Crossover Study in 3 Parts to Investigate the Effects of Multiple Doses of Ketoconazole (Part 1), Rifampicin (Part 2), and Ritonavir-boosted Atazanavir (Part 3) on the PK of a Single Dose of RO5093151 in Healthy Female & Male Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs RG 4929 (Primary) ; Atazanavir; Ketoconazole; Rifampicin; Ritonavir
- Indications Bacterial infections; Glaucoma; HIV infections
- Focus Pharmacokinetics
- Sponsors Roche
- 10 May 2012 New trial record